Gregory Sawicki

Publications

1. Electromyography-Informed Estimates of Joint Contact Forces Within the Lower Back and Knee Joints During a Diverse Set of Industry-Relevant Manual Lifting Tasks. J Appl Biomech. 2025 Jan 13; 1-10. View Abstract
2. "It's Like You're Feeding Your Child Twice": Barriers and Facilitators to Human Milk Feeding Children With Cystic Fibrosis. Pediatr Pulmonol. 2025 Jan; 60(1):e27497. View Abstract
3. Center of mass states render multijoint torques throughout standing balance recovery. J Neurophysiol. 2025 Jan 01; 133(1):206-221. View Abstract
4. What does it mean to be "healthy" when taking elexacaftor/tezacaftor/ivacaftor (ETI)? A qualitative study. J Cyst Fibros. 2025 Jan; 24(1):187-192. View Abstract
5. Qualitative understanding of experiences of people with cystic fibrosis in a treatment discontinuation trial: The QUEST study. Contemp Clin Trials. 2025 Jan; 148:107752. View Abstract
6. Reduced Achilles tendon stiffness in aging associates with higher metabolic cost of walking. J Appl Physiol (1985). 2024 Dec 01; 137(6):1541-1548. View Abstract
7. Plasma Microbial Cell-Free DNA Metagenomic Next-Generation Sequencing in People With Cystic Fibrosis. Pediatr Pulmonol. 2025 Jan; 60(1):e27380. View Abstract
8. Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis. Ann Am Thorac Soc. 2024 Nov; 21(11):1507-1515. View Abstract
9. Factors associated with prescription of elexacaftor/tezacaftor/ivacaftor among people with cystic fibrosis aged 12 years or older with at least one F508del allele. J Cyst Fibros. 2025 Jan; 24(1):135-141. View Abstract
10. Safety and tolerability of a low glycemic load dietary intervention in adults with cystic fibrosis: a pilot study. Front Nutr. 2024; 11:1441201. View Abstract
11. Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial. J Cyst Fibros. 2025 Jan; 24(1):91-97. View Abstract
12. Overview and Updates in Pediatric Pulmonary Medicine. Clin Chest Med. 2024 Sep; 45(3):xiii-xiv. View Abstract
13. Center of mass states render multi-joint torques throughout standing balance recovery. bioRxiv. 2024 Aug 19. View Abstract
14. Development and preliminary validation of the personalized cystic fibrosis medication questionnaire (PCF-MQ). J Cyst Fibros. 2024 Nov; 23(6):1100-1105. View Abstract
15. Cross-Cutting mHealth Behavior Change Techniques to Support Treatment Adherence and Self-Management of Complex Medical Conditions: Systematic Review. JMIR Mhealth Uhealth. 2024 May 01; 12:e49024. View Abstract
16. Advances in Care and Outcomes for Children with Cystic Fibrosis. Clin Chest Med. 2024 Sep; 45(3):625-637. View Abstract
17. The effects of plantarflexor weakness and reduced tendon stiffness with aging on gait stability. PLoS One. 2024; 19(4):e0302021. View Abstract
18. A Data-Driven Approach to Estimate Human Center of Mass State During Perturbed Locomotion Using Simulated Wearable Sensors. Ann Biomed Eng. 2024 Aug; 52(8):2013-2023. View Abstract
19. An emotional journey: caregiver experiences with gastrostomy tube decision-making for children with cystic fibrosis. J Cyst Fibros. 2024 Sep; 23(5):1000-1006. View Abstract
20. Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF. Front Endocrinol (Lausanne). 2024; 15:1293709. View Abstract
21. Habitually wearing high heels may improve user walking economy in any footwear. J Appl Physiol (1985). 2024 Mar 01; 136(3):567-572. View Abstract
22. Safety and Pharmacokinetics Following Oral or Intravenous Lefamulin in Adults With Cystic Fibrosis. Clin Ther. 2024 02; 46(2):96-103. View Abstract
23. Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis- Related Diabetes. Diabetes Care. 2024 Jan 01; 47(1):101-108. View Abstract
24. Reduced Achilles tendon stiffness in aging persists at matched activations and associates with higher metabolic cost of walking. bioRxiv. 2023 Nov 27. View Abstract
25. Clinician perspectives and practices related to sexual and reproductive care provision for males with cystic fibrosis. J Cyst Fibros. 2024 May; 23(3):417-423. View Abstract
26. Simulations suggest walking with reduced propulsive force would not mitigate the energetic consequences of lower tendon stiffness. PLoS One. 2023; 18(10):e0293331. View Abstract
27. Attenuation of muscle spindle firing with artificially increased series compliance during stretch of relaxed muscle. Exp Physiol. 2024 01; 109(1):148-158. View Abstract
28. Predictive Control of Peak Achilles Tendon Force in a Simulated System of the Human Ankle Joint with a Parallel Artificial Actuator During Hopping. IEEE Int Conf Rehabil Robot. 2023 09; 2023:1-6. View Abstract
29. American Society of Biomechanics Journal of Biomechanics Award 2021: Exploring the Functional Boundaries and Metabolic Consequences of Triceps Surae Force-Length Relations during Walking. J Biomech. 2023 09; 158:111771. View Abstract
30. Attenuation of muscle spindle firing with artificially increased series compliance during stretch of relaxed muscle. bioRxiv. 2023 May 09. View Abstract
31. Partners in research: The success with therapies research consortium and the CF community unite to improve self-management. J Cyst Fibros. 2023 09; 22(5):830-835. View Abstract
32. The influence of induced gait asymmetry on joint reaction forces. J Biomech. 2023 05; 153:111581. View Abstract
33. Perturbing the muscle work loop paradigm to unravel the neuromechanics of unsteady locomotion. J Exp Biol. 2023 04 01; 226(7). View Abstract
34. High deductible insurance plans impart economic burden for people with cystic fibrosis. Pediatr Pulmonol. 2023 06; 58(6):1798-1801. View Abstract
35. How many billions is enough? Prioritizing profits over patients with cystic fibrosis. Pediatr Pulmonol. 2023 05; 58(5):1595-1597. View Abstract
36. Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial. J Cyst Fibros. 2023 May; 22(3):464-470. View Abstract
37. EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS. J Cyst Fibros. 2023 May; 22(3):402-406. View Abstract
38. Clinician perspectives on assessing for disordered eating and body image disturbance in adolescents and young adults with cystic fibrosis. J Cyst Fibros. 2023 May; 22(3):431-435. View Abstract
39. Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. Lancet Respir Med. 2023 04; 11(4):329-340. View Abstract
40. Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation. Pulm Ther. 2022 Dec; 8(4):385-395. View Abstract
41. Sexual and reproductive health experiences and care of adult women with cystic fibrosis. J Cyst Fibros. 2023 03; 22(2):223-233. View Abstract
42. Real-world feasibility of short-term, unsupervised home spirometry in CF. Pediatr Pulmonol. 2022 12; 57(12):3129-3135. View Abstract
43. Eating disorders in adolescents and young adults with cystic fibrosis. Pediatr Pulmonol. 2022 11; 57(11):2791-2797. View Abstract
44. Author Reply to: Empowering Without Misinforming Adolescents and Young Adults with Cystic Fibrosis. Comment on "Perceptions of Social Media Use to Augment Health Care Among Adolescents and Young Adults With Cystic Fibrosis: Survey Study". JMIR Pediatr Parent. 2022 May 25; 5(2):e39450. View Abstract
45. Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis. J Clin Endocrinol Metab. 2022 03 24; 107(4):e1444-e1454. View Abstract
46. Understanding the Intersection between Gender Transition and Health Outcomes in Cystic Fibrosis. Ann Am Thorac Soc. 2022 03; 19(3):504-506. View Abstract
47. A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children = 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant. J Cyst Fibros. 2022 07; 21(4):675-683. View Abstract
48. Men's sexual and reproductive health in cystic fibrosis in the era of highly effective modulator therapies-A qualitative study. J Cyst Fibros. 2022 07; 21(4):657-661. View Abstract
49. Engaging Stakeholders in the Development of a Reproductive Goals Decision AID for Women with Cystic Fibrosis. J Patient Exp. 2022; 9:23743735221077527. View Abstract
50. The Relationship between Body Composition, Dietary Intake, Physical Activity, and Pulmonary Status in Adolescents and Adults with Cystic Fibrosis. Nutrients. 2022 Jan 12; 14(2). View Abstract
51. Exploring provider attitudes and perspectives related to men's health in cystic fibrosis. J Cyst Fibros. 2022 07; 21(4):652-656. View Abstract
52. Trajectories of the Transition Readiness Assessment Questionnaire Among Youth With Inflammatory Bowel Disease. J Clin Gastroenterol. 2022 10 01; 56(9):805-809. View Abstract
53. Financial impacts of the COVID-19 pandemic on cystic fibrosis care: lessons for the future. J Cyst Fibros. 2021 12; 20 Suppl 3:16-20. View Abstract
54. Patient and family experience of telehealth care delivery as part of the CF chronic care model early in the COVID-19 pandemic. J Cyst Fibros. 2021 12; 20 Suppl 3:41-46. View Abstract
55. Remote monitoring in telehealth care delivery across the U.S. cystic fibrosis care network. J Cyst Fibros. 2021 12; 20 Suppl 3:57-63. View Abstract
56. Evaluating barriers to and promoters of telehealth during the COVID-19 pandemic at U.S. cystic fibrosis programs. J Cyst Fibros. 2021 12; 20 Suppl 3:9-13. View Abstract
57. Prevalence, variability, and predictors of sinus surgery in pediatric patients with cystic fibrosis. Pediatr Pulmonol. 2021 12; 56(12):4029-4038. View Abstract
58. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis. J Cyst Fibros. 2022 03; 21(2):258-263. View Abstract
59. Favorable Clinician Acceptability of Telehealth as Part of the Cystic Fibrosis Care Model during the COVID-19 Pandemic. Ann Am Thorac Soc. 2021 09; 18(9):1588-1592. View Abstract
60. Perceptions of Social Media Use to Augment Health Care Among Adolescents and Young Adults With Cystic Fibrosis: Survey Study. JMIR Pediatr Parent. 2021 Aug 16; 4(3):e25014. View Abstract
61. Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design. Ann Am Thorac Soc. 2021 08; 18(8):1397-1405. View Abstract
62. Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. J Cyst Fibros. 2022 01; 21(1):96-103. View Abstract
63. The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis. J Clin Endocrinol Metab. 2021 03 08; 106(3):e1248-e1261. View Abstract
64. Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. Am J Respir Crit Care Med. 2021 03 01; 203(5):585-593. View Abstract
65. Rapid Implementation of Telehealth Services in a Pediatric Pulmonary Clinic During COVID-19. Pediatrics. 2021 07; 148(1). View Abstract
66. An evaluation of healthcare utilization and clinical charges in children and adults with cystic fibrosis. Pediatr Pulmonol. 2021 05; 56(5):928-938. View Abstract
67. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir Med. 2021 07; 9(7):733-746. View Abstract
68. Improvement of Pulmonary Function in Cystic Fibrosis Patients following Endoscopic Sinus Surgery. Laryngoscope. 2021 09; 131(9):1930-1938. View Abstract
69. Tribulations and (clinical) trials in cystic fibrosis. J Cyst Fibros. 2021 03; 20(2):188-190. View Abstract
70. Transition Readiness Not Associated With Measures of Health in Youth With IBD. Inflamm Bowel Dis. 2021 01 01; 27(1):49-57. View Abstract
71. Men's health in the modern era of cystic fibrosis. J Cyst Fibros. 2021 11; 20(6):e121-e123. View Abstract
72. Monogenic Diabetes in a Child with Cystic Fibrosis: A Case Report and Review of the Literature. J Endocr Soc. 2021 Jan 01; 5(1):bvaa165. View Abstract
73. Decreased survival in cystic fibrosis patients with a positive screen for depression. J Cyst Fibros. 2021 01; 20(1):120-126. View Abstract
74. Survey of patients with cystic fibrosis and caregivers decisions regarding CFTR modulators. Pediatr Pulmonol. 2020 11; 55(11):2983-2989. View Abstract
75. Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis. J Pediatr. 2019 12; 215:164-171.e2. View Abstract
76. Male gender and unemployment are associated with lower levels of perceived social support in adults with cystic fibrosis. J Psychosom Res. 2019 12; 127:109858. View Abstract
77. Medical Deferred Action - Living on Borrowed Time. N Engl J Med. 2019 Oct 24; 381(17):1601-1603. View Abstract
78. Predictors of pulmonary exacerbation treatment in cystic fibrosis. J Cyst Fibros. 2020 05; 19(3):407-414. View Abstract
79. A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11?years with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):708-713. View Abstract
80. Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. J Cyst Fibros. 2020 01; 19(1):68-79. View Abstract
81. Chronic rhino-sinusitis treatment in children with cystic fibrosis: A cross-sectional survey of pediatric pulmonologists and otolaryngologists. Int J Pediatr Otorhinolaryngol. 2019 Sep; 124:139-142. View Abstract
82. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5?years (KLIMB). J Cyst Fibros. 2019 11; 18(6):838-843. View Abstract
83. Developing Sexual and Reproductive Health Educational Resources for Young Women with Cystic Fibrosis: A Structured Approach to Stakeholder Engagement. Patient. 2019 04; 12(2):267-276. View Abstract
84. Linkage of the CF foundation patient registry with the pediatric health information system database. Pediatr Pulmonol. 2019 06; 54(6):721-728. View Abstract
85. Interprofessional provider educational needs and preferences regarding the provision of sexual and reproductive health care in cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):671-676. View Abstract
86. Social support is associated with fewer reported symptoms and decreased treatment burden in adults with cystic fibrosis. J Cyst Fibros. 2019 07; 18(4):572-576. View Abstract
87. Cystic Fibrosis And Ivacaftor Use: The Authors Reply. Health Aff (Millwood). 2019 02; 38(2):328. View Abstract
88. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Lancet Respir Med. 2019 04; 7(4):325-335. View Abstract
89. Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010-2016. Pediatr Pulmonol. 2018 12; 53(12):1611-1618. View Abstract
90. Disparities in Mortality of Hispanic Patients with Cystic Fibrosis in the United States. A National and Regional Cohort Study. Am J Respir Crit Care Med. 2018 10 15; 198(8):1055-1063. View Abstract
91. Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. J Clin Transl Sci. 2018 Oct; 2(5):334-342. View Abstract
92. Rate and predictors of prescription of lumacaftor - Ivacaftor in the 18?months following approval in the United States. J Cyst Fibros. 2018 11; 17(6):742-746. View Abstract
93. Sexual and Reproductive Health of Young Women With Cystic Fibrosis: A Concept Mapping Study. Acad Pediatr. 2019 04; 19(3):307-314. View Abstract
94. The burden of cystic fibrosis in the Medicaid population. Clinicoecon Outcomes Res. 2018; 10:423-431. View Abstract
95. Overcoming psychosocial challenges in cystic fibrosis: Promoting resilience. Pediatr Pulmonol. 2018 11; 53(S3):S86-S92. View Abstract
96. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax. 2018 08; 73(8):731-740. View Abstract
97. Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosis-Related Hospitalizations. Health Aff (Millwood). 2018 05; 37(5):773-779. View Abstract
98. Perspectives of adolescent girls with cystic fibrosis and parents on disease-specific sexual and reproductive health education. Pediatr Pulmonol. 2018 08; 53(8):1027-1034. View Abstract
99. Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. Ann Am Thorac Soc. 2018 04; 15(4):485-493. View Abstract
100. Cystic fibrosis patient registries: A valuable source for clinical research. J Cyst Fibros. 2018 07; 17(4):433-440. View Abstract
101. Outcome evaluation of a pharmacy-based therapy management program for patients with cystic fibrosis. Pediatr Pulmonol. 2018 06; 53(6):720-727. View Abstract
102. Risk Factors for Gaps in Care during Transfer from Pediatric to Adult Cystic Fibrosis Programs in the United States. Ann Am Thorac Soc. 2018 02; 15(2):234-240. View Abstract
103. Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis. J Cyst Fibros. 2018 05; 17(3):e25-e31. View Abstract
104. Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation. J Cyst Fibros. 2018 07; 17(4):503-510. View Abstract
105. Sexual and reproductive health care utilization and preferences reported by young women with cystic fibrosis. J Cyst Fibros. 2018 01; 17(1):64-70. View Abstract
106. Mental Health Screening of Medically-Admitted Patients With Cystic Fibrosis. Psychosomatics. 2018 Mar - Apr; 59(2):158-168. View Abstract
107. Incident Stenotrophomonas maltophilia infection and lung function decline in cystic fibrosis. Pediatr Pulmonol. 2017 10; 52(10):1276-1282. View Abstract
108. Early Lung Function Decline in Cystic Fibrosis. Can Registry Data Explain Divergent Phenotypes? Am J Respir Crit Care Med. 2017 08 15; 196(4):407-409. View Abstract
109. Pediatric lung transplantation and end of life care in cystic fibrosis: Barriers and successful strategies. Pediatr Pulmonol. 2017 Nov; 52(S48):S61-S68. View Abstract
110. Sexual and reproductive health behaviors and experiences reported by young women with cystic fibrosis. J Cyst Fibros. 2018 01; 17(1):57-63. View Abstract
111. Preparation for Transition to Adult Care Among Medicaid-Insured Adolescents. Pediatrics. 2017 Jul; 140(1). View Abstract
112. Patients with Cystic Fibrosis and a G551D or Homozygous F508del Mutation: Similar Lung Function Decline. Am J Respir Crit Care Med. 2017 06 15; 195(12):1673-1676. View Abstract
113. Impact of an Individual Mandate and Other Health Reforms on Dependent Coverage for Adolescents and Young Adults. Health Serv Res. 2018 06; 53(3):1581-1599. View Abstract
114. Utilization of a patient-centered asthma passport tool in a subspecialty clinic. J Asthma. 2018 02; 55(2):180-187. View Abstract
115. Microbiology of the Upper and Lower Airways in Pediatric Cystic Fibrosis Patients. Otolaryngol Head Neck Surg. 2017 08; 157(2):302-308. View Abstract
116. Correlation of Transient Elastography With Severity of Cystic Fibrosis-related Liver Disease. J Pediatr Gastroenterol Nutr. 2017 04; 64(4):505-511. View Abstract
117. The CF-CARES primary palliative care model: A CF-specific structured assessment of symptoms, distress, and coping. J Cyst Fibros. 2018 01; 17(1):71-77. View Abstract
118. Adherence and Recursive Perception Among Young Adults with Cystic Fibrosis. Anthropol Med. 2017 Apr; 24(1):65-80. View Abstract
119. Counterpoint: Too little care or too little collaboration: Approaches to treatment refusal in CF. J Cyst Fibros. 2017 03; 16(2):304-305. View Abstract
120. Provider Attitudes and Practices toward Sexual and Reproductive Health Care for Young Women with Cystic Fibrosis. J Pediatr Adolesc Gynecol. 2017 Oct; 30(5):546-552. View Abstract
121. Reply: Combining Clinical Trial and Patient Registry Data in Cystic Fibrosis: Who Should Be Compared? Am J Respir Crit Care Med. 2017 02 01; 195(3):405-406. View Abstract
122. Obesity and Airway Dysanapsis in Children with and without Asthma. Am J Respir Crit Care Med. 2017 Feb 01; 195(3):314-323. View Abstract
123. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2017 02; 5(2):107-118. View Abstract
124. Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder. Patient Prefer Adherence. 2016; 10:2163-2169. View Abstract
125. Strategies to optimize treatment adherence in adolescent patients with cystic fibrosis. Adolesc Health Med Ther. 2016; 7:117-124. View Abstract
126. Transition and transfer of childhood cancer survivors to adult care: A national survey of pediatric oncologists. Pediatr Blood Cancer. 2017 02; 64(2):346-352. View Abstract
127. Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis. J Med Econ. 2016 Sep; 19(9):845-51. View Abstract
128. Young adults with cystic fibrosis have altered trabecular microstructure by ITS-based morphological analysis. Osteoporos Int. 2016 08; 27(8):2497-505. View Abstract
129. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med. 2016 Feb; 4(2):107-15. View Abstract
130. Risk Factors for Hearing Loss in Patients with Cystic Fibrosis. J Am Acad Audiol. 2016 01; 27(1):6-12. View Abstract
131. CF RISE: Implementing a Clinic-Based Transition Program. Pediatr Allergy Immunol Pulmonol. 2015 Dec; 28(4):250-254. View Abstract
132. Tackling the increasing complexity of CF care. Pediatr Pulmonol. 2015 Oct; 50 Suppl 40:S74-9. View Abstract
133. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med. 2015 Oct 01; 192(7):836-42. View Abstract
134. Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. J Pediatr. 2015 Nov; 167(5):1081-8.e1. View Abstract
135. Development and Validation of the Adolescent Assessment of Preparation for Transition: A Novel Patient Experience Measure. J Adolesc Health. 2015 Sep; 57(3):282-7. View Abstract
136. Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry. Ann Am Thorac Soc. 2015 Aug; 12(8):1146-52. View Abstract
137. A randomized controlled trial of vitamin D replacement strategies in pediatric CF patients. J Cyst Fibros. 2016 Mar; 15(2):234-41. View Abstract
138. Self-Management and Transition Readiness Assessment: Concurrent, Predictive and Discriminant Validation of the STARx Questionnaire. J Pediatr Nurs. 2015 Sep-Oct; 30(5):668-76. View Abstract
139. Predictors of timing of transfer from pediatric- to adult-focused primary care. JAMA Pediatr. 2015 Jun; 169(6):e150951. View Abstract
140. Similar performance of Brasfield and Wisconsin scoring systems in young children with cystic fibrosis. Pediatr Radiol. 2015 Oct; 45(11):1624-8. View Abstract
141. Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients. J Cyst Fibros. 2015 Nov; 14(6):777-83. View Abstract
142. Development and evaluation of a palliative care curriculum for cystic fibrosis healthcare providers. J Cyst Fibros. 2016 Jan; 15(1):90-5. View Abstract
143. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site. Pediatr Pulmonol. 2015 May; 50(5):431-40. View Abstract
144. Ready, set, stop: mismatch between self-care beliefs, transition readiness skills, and transition planning among adolescents, young adults, and parents. Clin Pediatr (Phila). 2014 Oct; 53(11):1062-8. View Abstract
145. The Transition Readiness Assessment Questionnaire (TRAQ): its factor structure, reliability, and validity. Acad Pediatr. 2014 Jul-Aug; 14(4):415-22. View Abstract
146. Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis. J Clin Endocrinol Metab. 2014 Sep; 99(9):3399-407. View Abstract
147. Inter-hospital variation in the frequency of sinus surgery in children with cystic fibrosis. Pediatr Pulmonol. 2015 Mar; 50(3):231-235. View Abstract
148. Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives. Pediatr Pulmonol. 2015 Feb; 50(2):127-36. View Abstract
149. Transition care: future directions in education, health policy, and outcomes research. Acad Pediatr. 2014 Mar-Apr; 14(2):120-7. View Abstract
150. Vitamin D status in children with cystic fibrosis. Associations with inflammation and bacterial colonization. Ann Am Thorac Soc. 2014 Feb; 11(2):205-10. View Abstract
151. Transition and transfer of adolescents and young adults with pediatric onset chronic disease: the patient and parent perspective. J Pediatr Rehabil Med. 2014; 7(1):43-51. View Abstract
152. Brasfield and Wisconsin scoring systems have equal value as outcome assessment tools of cystic fibrosis lung disease. Pediatr Radiol. 2014 May; 44(5):529-34. View Abstract
153. Longitudinal trends in health-related quality of life in adults with cystic fibrosis. Chest. 2013 Sep; 144(3):981-989. View Abstract
154. Claim-based analyses of inhaled corticosteroid refill rates for asthma: who's kidding whom? Ann Am Thorac Soc. 2013 Apr; 10(2):149-50. View Abstract
155. Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. J Cyst Fibros. 2013 Sep; 12(5):461-7. View Abstract
156. A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care. Pediatr Pulmonol. 2013 Oct; 48(10):954-61. View Abstract
157. Referral patterns and perceived barriers to adult congenital heart disease care: results of a survey of U.S. pediatric cardiologists. J Am Coll Cardiol. 2012 Dec 11; 60(23):2411-8. View Abstract
158. Managing treatment complexity in cystic fibrosis: challenges and opportunities. Pediatr Pulmonol. 2012 Jun; 47(6):523-33. View Abstract
159. Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample. Qual Life Res. 2012 Sep; 21(7):1279-90. View Abstract
160. The impact of reflux burden on Pseudomonas positivity in children with cystic fibrosis. Pediatr Pulmonol. 2012 Jun; 47(6):582-7. View Abstract
161. Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Qual Life Res. 2012 Sep; 21(7):1267-78. View Abstract
162. Physician practices for communicating with patients with cystic fibrosis about the use of noninvasive and invasive mechanical ventilation. Chest. 2012 Apr; 141(4):1010-1017. View Abstract
163. Assessment of current strategies for weaning premature infants from supplemental oxygen in the outpatient setting. Adv Neonatal Care. 2011 Oct; 11(5):349-56. View Abstract
164. Receipt of health care transition counseling in the national survey of adult transition and health. Pediatrics. 2011 Sep; 128(3):e521-9. View Abstract
165. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol. 2012 Jan; 47(1):44-52. View Abstract
166. Tree nut allergy, egg allergy, and asthma in children. Clin Pediatr (Phila). 2011 Feb; 50(2):133-9. View Abstract
167. Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. Pediatr Pulmonol. 2011 Jan; 46(1):36-44. View Abstract
168. Employment experiences among adolescents and young adults with cystic fibrosis. Disabil Rehabil. 2011; 33(11):922-6. View Abstract
169. Associations between illness perceptions and health-related quality of life in adults with cystic fibrosis. J Psychosom Res. 2011 Feb; 70(2):161-7. View Abstract
170. Uncontrolled asthma in a commercially insured population from 2002 to 2007: trends, predictors, and costs. J Asthma. 2010 Jun; 47(5):574-80. View Abstract
171. Cystic fibrosis and transition to adult medical care. Pediatrics. 2010 Mar; 125(3):566-73. View Abstract
172. Asthma care quality for children with minority-serving providers. Arch Pediatr Adolesc Med. 2010 Jan; 164(1):38-45. View Abstract
173. Patterns of inhaled corticosteroid use and asthma control in the Childhood Asthma Management Program Continuation Study. Ann Allergy Asthma Immunol. 2010 Jan; 104(1):30-5. View Abstract
174. Measuring the transition readiness of youth with special healthcare needs: validation of the TRAQ--Transition Readiness Assessment Questionnaire. J Pediatr Psychol. 2011 Mar; 36(2):160-71. View Abstract
175. Travel patterns to school among children with asthma. Clin Pediatr (Phila). 2009 Jul; 48(6):632-40. View Abstract
176. The impact of MRSA on lung function in patients with cystic fibrosis. Am J Respir Crit Care Med. 2009 Apr 15; 179(8):734-5; author reply 735. View Abstract
177. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr Pulmonol. 2008 Nov; 43(11):1117-1123. View Abstract
178. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2009 Mar; 8(2):91-6. View Abstract
179. Advance care planning in adults with cystic fibrosis. J Palliat Med. 2008 Oct; 11(8):1135-41. View Abstract
180. Necrotising pneumonia is an increasingly detected complication of pneumonia in children. Eur Respir J. 2008 Jun; 31(6):1285-91. View Abstract
181. Self-reported physical and psychological symptom burden in adults with cystic fibrosis. J Pain Symptom Manage. 2008 Apr; 35(4):372-80. View Abstract
182. Periodic use of inhaled steroids in children with mild persistent asthma: what are pediatricians recommending? Clin Pediatr (Phila). 2008 Jun; 47(5):446-51. View Abstract
183. Bronchoscopy findings in children and young adults with tracheostomy due to congenital anomalies and neurological impairment. J Pediatr Rehabil Med. 2008; 1(2):137-43. View Abstract
184. Mucoepidermoid carcinoma of bronchus in a pediatric patient: (18)F-FDG PET findings. Pediatr Radiol. 2007 Dec; 37(12):1278-82. View Abstract
185. Self-reported involvement of family members in the care of adults with CF. J Cyst Fibros. 2008 Mar; 7(2):95-101. View Abstract
186. Adults with cystic fibrosis report important and unmet needs for disease information. J Cyst Fibros. 2007 Nov 30; 6(6):411-6. View Abstract
187. Phenotypic and cytokine analysis of human peripheral blood gamma delta T cells expressing NK cell receptors. J Immunol. 1997 Oct 15; 159(8):3723-30. View Abstract
Show All Publications Show Fewer Publications